Navigation Links
Cardica Announces Proposed Public Offering of Common Stock
Date:3/14/2013

REDWOOD CITY, Calif., March 14, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Wedbush PacGrow Life Sciences is acting as sole manager for the offering.

The shares described above are being offered by Cardica pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on February 7, 2011.  A preliminary prospectus supplement is available for free by visiting EDGAR on the SEC's website located at www.sec.gov.  Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from the offices of Wedbush Securities Inc., One Bush Street , 17th Floor, San Francisco, CA  94104, Attn:  ECM Prospectus Department, by calling 415-274-6819, or by email at vinnie.devone@wedbush.com.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cardica

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. 

Forward-Looking Statements

Statements contained in this p
'/>"/>

SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cardica Announces Fiscal 2012 Third Quarter Financial Results
2. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
3. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica Announces Fiscal 2013 Second Quarter Financial Results
9. Cardica Updates Enrollment Progress In European Clinical Trial
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Nile Therapeutics,Inc. (Nasdaq: NLTX ), today announced ... failure patient in its Phase IIa, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... The primary objective of the Phase IIa study ...
... 10 Medarex, Inc.,(Nasdaq: MEDX ) today ... in research discovery and antibody development, and the,multiple ... value.,In addition, comprehensive updates on current and future ... were presented by Medarex,s,President and CEO, Howard H. ...
Cached Medicine Technology:Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients 2Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients 3Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 2Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 3Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 4Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 5Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City 6
(Date:7/11/2014)... July 11, 2014 Global enterprises today ... to outsource day-to-day management activities. Managed services offer these ... expenses. The economic slowdown resulted into rising operational costs ... expenses is considered to be the global market driver ... , The global managed services market is estimated to ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... who drink more than 15 drinks of alcohol a ... like anxiety disorder and depression. ,Researchers of University ... the study said that there is a significant link ... research study has been the largest longitudinal study in ...
... Health, US, have found out //that almost 50% of the ... early as the teenage and may remain undetected for a ... in spite of efficient treatments available, patients stay untreated for ... disorders once diagnosed, difficult to treat as they become more ...
... Gold nanoparticles may be used to detect cancer, says a ... ,The father and son research team had been able ... cells, a process that will make the tracing of cancer ... called epidermal growth factor receptor (EFGR) over their surface. This ...
... screening of the mouth by trained health workers can help ... the oral cancer mortality rate. ,A research done by ... possible to visually screen people for oral cancer in order ... of oral cancer patients. ,Oral cancer is the growth ...
... women take is affected by factors like stress, mood, //anxiety ... the American Dietetic Association. ,Diet in pregnancy is very ... contain the food elements like folic acid and other vitamins ... women who are more often exhausted or stressed tend to ...
... cancer may have higher risks of having cognitive// impairment ... of Southern California had found that patients who survived ... as much risk as their healthy counterparts of having ... of cancer and their twins with the help of ...
Cached Medicine News:
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
... for applications such as vasectomy that ... ,The autoclavable handpiece with six-foot cord ... cautery electrodes, allowing the physician to ... wide variety of procedures., ,The 2201 ...
No Scalpel Vasectomy Hemostat 5 1/2" (14cm), smooth sharp point, curved, gold finger rings...
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company....
Medicine Products: